Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Status:
Completed
Trial end date:
2018-02-05
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to compare progression-free survival in patients with
multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus
dexamethasone or bortezomib plus dexamethasone.